These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 32470562)

  • 61. Is irritable bowel syndrome an infectious disease?
    Thompson JR
    World J Gastroenterol; 2016 Jan; 22(4):1331-4. PubMed ID: 26819502
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania.
    Moraru IG; Moraru AG; Andrei M; Iordache T; Drug V; Diculescu M; Portincasa P; Dumitrascu DL
    Rom J Intern Med; 2014; 52(3):143-50. PubMed ID: 25509557
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Irritable bowel syndrome and gut microbiota.
    Canakis A; Haroon M; Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2020 Feb; 27(1):28-35. PubMed ID: 31789724
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Faecal calprotectin levels after rifaximin treatment in patients with irritable bowel syndrome with diarrhoea: A single-center prospective study.
    Safwat E; Salah M; Hussein H
    Arab J Gastroenterol; 2020 Dec; 21(4):273-277. PubMed ID: 32928705
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome.
    Vicari E; Salemi M; Sidoti G; Malaguarnera M; Castiglione R
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29099760
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation.
    Tanaka Y; Yamashita R; Kawashima J; Mori H; Kurokawa K; Fukuda S; Gotoh Y; Nakamura K; Hayashi T; Kasahara Y; Sato Y; Fukudo S
    J Gastroenterol; 2022 Oct; 57(10):748-760. PubMed ID: 35908139
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Fecal bacteria and short-chain fatty acids in irritable bowel syndrome: Relations to subtype.
    Teige ES; Hillestad EMR; Steinsvik EK; Brønstad I; Lundervold A; Lundervold AJ; Valeur J; Hausken T; Berentsen B; Lied GA
    Neurogastroenterol Motil; 2024 Sep; 36(9):e14854. PubMed ID: 38946176
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sex-based differences in fecal short-chain fatty acid and gut microbiota in irritable bowel syndrome patients.
    Sun QH; Liu ZJ; Zhang L; Wei H; Song LJ; Zhu SW; He MB; Duan LP
    J Dig Dis; 2021 May; 22(5):246-255. PubMed ID: 33822477
    [TBL] [Abstract][Full Text] [Related]  

  • 69. New treatment options for irritable bowel syndrome with predominant diarrhea.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):25-30. PubMed ID: 27875419
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Randomized clinical trial: Effects of Aloe barbadensis Mill. extract on symptoms, fecal microbiota and fecal metabolite profiles in patients with irritable bowel syndrome.
    Ahluwalia B; Magnusson MK; Böhn L; Störsrud S; Larsson F; Savolainen O; Ross A; Simrén M; Öhman L
    Neurogastroenterol Motil; 2020 Aug; 32(8):e13860. PubMed ID: 32314514
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
    DuPont HL
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Mucosal-Associated Microbiota Other Than Luminal Microbiota Has a Close Relationship With Diarrhea-Predominant Irritable Bowel Syndrome.
    Yang M; Hong G; Jin Y; Li Y; Li G; Hou X
    Front Cell Infect Microbiol; 2020; 10():515614. PubMed ID: 33224895
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The clinical value of breath ammonia determination in patients with irritable bowel syndrome.
    Chojnacki C; Błońska A; Mędrek-Socha M; Chojnacki M; Konrad P
    Pol Merkur Lekarski; 2022 Dec; 50(300):360-363. PubMed ID: 36645681
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Involvement of mucosal flora and enterochromaffin cells of the caecum and descending colon in diarrhoea-predominant irritable bowel syndrome.
    Yang J; Wang P; Liu T; Lin L; Li L; Kou G; Zhou R; Li P; Li Y
    BMC Microbiol; 2021 Nov; 21(1):316. PubMed ID: 34773967
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Intestinal Fungal Dysbiosis Is Associated With Visceral Hypersensitivity in Patients With Irritable Bowel Syndrome and Rats.
    Botschuijver S; Roeselers G; Levin E; Jonkers DM; Welting O; Heinsbroek SEM; de Weerd HH; Boekhout T; Fornai M; Masclee AA; Schuren FHJ; de Jonge WJ; Seppen J; van den Wijngaard RM
    Gastroenterology; 2017 Oct; 153(4):1026-1039. PubMed ID: 28624575
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Distinct Microbial Populations Exist in the Mucosa-associated Microbiota of Diarrhea Predominant Irritable Bowel Syndrome and Ulcerative Colitis.
    Zhong W; Lu X; Shi H; Zhao G; Song Y; Wang Y; Zhang J; Jin Y; Wang S
    J Clin Gastroenterol; 2019 Oct; 53(9):660-672. PubMed ID: 29210899
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Microscopic colitis and small intestinal bacterial overgrowth--diagnosis behind the irritable bowel syndrome?
    Stoicescu A; Andrei M; Becheanu G; Stoicescu M; Nicolaie T; Diculescu M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(3):766-72. PubMed ID: 23272525
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.
    Zhao J; Zheng X; Chu H; Zhao J; Cong Y; Fried M; Fox M; Dai N
    Neurogastroenterol Motil; 2014 Jun; 26(6):794-802. PubMed ID: 24641100
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The function of the gut microbiota-bile acid-TGR5 axis in diarrhea-predominant irritable bowel syndrome.
    Zhan K; Wu H; Xu Y; Rao K; Zheng H; Qin S; Yang Y; Jia R; Chen W; Huang S
    mSystems; 2024 Mar; 9(3):e0129923. PubMed ID: 38329942
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.
    Schoenfeld P; Pimentel M; Chang L; Lembo A; Chey WD; Yu J; Paterson C; Bortey E; Forbes WP
    Aliment Pharmacol Ther; 2014 May; 39(10):1161-8. PubMed ID: 24697851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.